• 06.02.16

    Peter Goss Discusses FDA Approval of New Implant for Opioid Addiction Treatment

    Peter J. Goss was interviewed by Law360 for an article analyzing the FDA’s recent approval of an implantable version of an opioid addiction drug, Probuphine.  (“FDA's Opioid Implant Nod Shows Pressure To Curb Addiction,” available to Law360 subscribers here.)  Goss noted that the FDA has been under pressure to curb the opioid abuse epidemic, and that the approval of the Probuphine implant adds “one more tool … to the overall toolkit physicians will have for treating opioid addicts.” Mr. Goss focuses his national practice on pharmaceutical and medical device product liability litigation and toxic torts. He has represented global pharmaceutical, medical technology, and chemical firms in hundreds…
  • 11.19.15


    Blackwell Burke P.A. has been included on the 2016 U.S. News & World Report and Best Lawyers Best Law Firms list with a ranking of Metropolitan Tier 1 for Products Liability Litigation – Defendant, and a Tier 2 ranking under Mass Tort Litigation/Class Actions – Defendants.The U.S. News – Best Lawyers "Best Law Firms" rankings are based on a rigorous evaluation process that includes the collection of client and lawyer evaluations, peer review from leading attorneys, and review of additional information provided by law firms as part of the formal submission process.  Feedback was obtained from clients in various areas,…
  • 11.15.15


    Blackwell Burke P.A. has been ranked as “Highly Recommended” in the 2016 Edition of Benchmark Litigation, one of just eight Minnesota firms to receive that recognition.  Firm Founder and CEO Jerry Blackwell, partners Corey Gordon, Peter Goss, Benjamin Hulse, and special counsel Mike Hatch have all been named Minnesota Litigation Stars.  Partner Mary Young was named a Minnesota Future Star.“Highly Recommended” firms are those consistently acknowledged by clients and competitors and held as dominant in their particular jurisdiction during Benchmark Litigation’s six-month research process.  Blackwell Burke also was ranked “Highly Recommended” in the 2015 Edition of Benchmark Litigation.   The “Litigation…
  • 10.01.15

    Peter Goss Shares Advice on Avoiding Attorney-Client Privilege Blunders

    RE: Website UpdatePeter J. Goss recently commented for a Law360 article entitled “The 3 Biggest Blunders With Attorney-Client Privilege.”  Goss cautioned that written memoranda containing advice on changes to business practices are often difficult or impossible to “claw back” after inadvertent disclosure.  These memoranda can prove troublesome when they recommend a course of action that the company ultimately decides not to take.  For that reason, Goss recommends that lawyers confer closely with the affected businesspeople before reducing their advice to writing.  “This is important for the lawyers involved in generating a piece of writing that could affect a course of…
  • 08.25.15

    Peter J. Goss Discusses $71 Million Amgen Off-Label Marketing Settlement in Law360

    Law360 quoted Peter J. Goss in its analysis of the recent $71 million settlement between Amgen and the Attorneys General of 48 states and the District of Columbia over alleged off-label marketing of two of the company’s blockbuster drugs, Enbrel and Aranesp.  Goss commented that the settlement was driven by a December 2012 settlement of essentially the same allegations with the U.S. Department of Justice: “At the point of such a federal settlement, it was a foregone conclusion that Amgen would have to deal with the states separately and that there probably would need to be a settlement with them…
  • 08.10.15

    Peter J. Goss Quoted on “Product Liability Cases To Watch In The Second Half Of 2015”

    Law360 interviewed Peter Goss for an article discussing noteworthy product liability cases that are currently pending.  Goss cited the federal multi-district litigation over the cholesterol drug Lipitor and the increased risk of diabetes allegedly associated with its use.  "Millions of Americans have diabetes, and millions of people take Lipitor, and it would potentially open the door to some significant litigation if the plaintiffs were to prevail in an early bellwether trial in this litigation," said Goss.  Goss also noted that the plaintiffs in the Zoloft birth defects litigation have yet to win a trial, and commented that “[W]e won't be…

Interested in learning more?

Email Disclaimer Close

Sending us an email will not make you a client of our firm. Until we have agreed to represent you, nothing you send us will be confidential or privileged.

If your email is related to representation, the best way for you to inquire about a possible representation is to call a Blackwell Burke P.A. attorney at one of the telephone numbers listed on our Attorney's page. An attorney will first take you through our conflict of interest procedure and see that you are put in touch with the lawyer best suited to handle your matter.

If you proceed with an email, you confirm that you have read and understand this notice. To proceed, click I Agree.